168650-46-2
![[Asp371]-Tyrosinase (369-377), human Chemical Structure](http://file.medchemexpress.cn/product_pic/hy-p1919.gif "[Asp371]-Tyrosinase (369-377), human Chemical Structure")
168650-46-2
Chemical Structure
[Asp371]-Tyrosinase (369-377), human
- CAS No.: 168650-46-2
- Formula:C42H66N10O16S2
- Molecular Weight:1031.16
InChIKey: MFDQNJLLKIATDB-ZSGRDTBASA-N
SMILES: OC1=CC=C(C[C@@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](C(C)C)C(O)=O)=O)CCC(N)=O)=O)CO)=O)CCSC)=O)[C@@H](C)O)=O)=O)CC(O)=O)=O)CCSC)=O)N)C=C1
Biological Activity: Tyrosinase 369-377, human is a HLA-A2.1-restricted epitope derived from tyrosinase, has been used to develop tumor-targeted vaccines with mixed efficacy[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
[Asp371]-Tyrosinase (369-377), human | 99.66% | Tyrosinase 369-377, human is a HLA-A2.1-restricted epitope derived from tyrosinase, has been used to develop tumor-targeted vaccines with mixed efficacy. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Guillaume B, et al. Analysis of the processing of seven human tumor antigens by intermediate proteasomes. J Immunol. 2012 Oct 1;189(7):3538-47. [Content Brief]
- [2]. Mitchell MS, et al. Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope. J Clin Oncol. 2002 Feb 15;20(4):1075-86. [Content Brief]
Keywords
